BiotechTube

Romiplostim + Placebo

Phase 3Completed
2 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Immune Thrombocytopenia

Conditions

Immune Thrombocytopenia

Trial Timeline

Sep 1, 2015 → Jun 1, 2017

NCT ID
NCT02868099

About Romiplostim + Placebo

Romiplostim + Placebo is a phase 3 stage product being developed by Kyowa Kirin for Immune Thrombocytopenia. The current trial status is completed. This product is registered under clinical trial identifier NCT02868099. Target conditions include Immune Thrombocytopenia.

What happened to similar drugs?

7 of 20 similar drugs in Immune Thrombocytopenia were approved

Approved (7) Terminated (2) Active (13)
✅Lopinavir 400 mg/ritonavir 100 mg + EfavirenzGilead SciencesApproved
✅IgPro10CSLApproved
✅Subcutaneous Immune Globulin (Human) (Hizentra)CSLApproved
✅Methylprednisolone + PrednisoloneBiogenApproved
✅Flebogamma 5% DIFGrifolsApproved
✅Asceniv™ADMA BiologicsApproved
✅BivigamADMA BiologicsApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02868099Phase 3Completed

Competing Products

20 competing products in Immune Thrombocytopenia

See all competitors
ProductCompanyStageHype Score
Pirtobrutinib + PlaceboEli LillyPhase 1/2
39
Anti-(integrin beta-3) human monoclonal antibodyRallybioPhase 2
17
SatralizumabChugai PharmaceuticalPhase 3
47
Placebo + LusutrombopagShionogiPhase 2
27
LusutrombopagShionogiPhase 2
27
RomiplostimKyowa KirinPhase 1/2
32
AMG 531Kyowa KirinPhase 2/3
38
Romiplostim (AMG-531)Kyowa KirinPhase 2
35
Romiplostim and danazolKyowa KirinPhase 2
31
Hetrombopag OlamineJiangsu Hengrui MedicinePhase 1
29
SHR0302 quick release tablets + SHR0302 sustained-release tabletsJiangsu Hengrui MedicinePhase 1
29
Hetrombopag + PlaceboJiangsu Hengrui MedicinePhase 3
40
HR19042 Capsule, Tarpeyo®, Budenofalk®Jiangsu Hengrui MedicinePhase 1
29
HR19042 CapsulesJiangsu Hengrui MedicinePhase 2
35
HerombopagJiangsu Hengrui MedicinePhase 3
36
Zostavax®MerckPre-clinical
18
Raltegravir + AtazanavirMerckPre-clinical
26
ZostavaxMerckPre-clinical
26
MK-8723 + Matching PlaceboMerckPhase 1
29
Eltrombopag (Revolade®) + standard therapy (without eltrombopag): HD-DXMNovartisPhase 2
35